Table III.

Univariate and multivariate analyses to evaluate the predictors of the time to progression of bone metastasis.

		Univariate analysis		Multivariate analysis
Variable	n	HR (95% CI)	P-value	HR (95%CI)	P-value
IMDC risk stratification
Favorable	11	1 (reference)		1 (reference)
Intermediate	23	1.88 (0.66–5.33)	0.234	1.79 (0.55–5.90)	0.336
Poor	10	1.47 (0.45–4.82)	0.527	1.24 (0.36–4.21)	0.735
Bone-modifying agents
Yes	17	1 (reference)		1 (reference)
No	27	3.07 (1.28–7.38)	0.012	1.45 (0.53–4.00)	0.473
Systemic therapy
With radiotherapy	29	1 (reference)		1 (reference)
Without radiotherapy	15	12.62 (4.17–38.25)	<0.0001	16.60 (4.53–60.90)	<0.0001
Systemic therapy regimen after diagnosis of bone metastasis
Targeted therapy	36	1 (reference)		1 (reference)
Immune checkpoint inhibitor	8	2.17 (0.84–5.59)	0.108	2.88 (0.88–9.43)	0.080

IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; HR, hazard ratio.